Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.

Area of Science:

• Pulmonology
• Pharmacology
• Clinical Practice Guidelines

Background:

• International collaboration to update clinical practice guidelines for interstitial lung disease (ILD).
• Focus on evaluating antifibrotic nintedanib for progressive pulmonary fibrosis (PPF).

Purpose of the Study:

• Systematic review of existing ILD literature.
• Determine efficacy and safety of nintedanib in PPF patients.

Main Methods:

• Literature search across MEDLINE, EMBASE, and Cochrane databases.
• Extracted data on mortality, disease progression, and adverse events.
• Utilized Grading of Recommendations, Assessment, Development and Evaluation (GRADE) for evidence quality.

Main Results:

• Two studies included; nintedanib reduced annual decline in forced vital capacity across various PPF subtypes compared to placebo.
• Statistically significant benefit observed in usual interstitial pneumonia (UIP) and non-UIP patterns.
• Gastrointestinal side effects were common; evidence quality ranged from very low to moderate.

Conclusions:

• Nintedanib use in PPF shows a statistically significant decrease in disease progression.
• Increased gastrointestinal side effects noted, irrespective of radiographic pattern.
• Low certainty in effect estimates due to evidence limitations hinders definitive subtype-specific conclusions.